Post COVID-19 acquired haemophilia A treated with recombinant porcine factor VIII

Streszczenie

Acquired haemophilia A (AHA) is a rare bleeding disorder resulting from autoimmune reaction
against factor VIII, which may occur in patients with viral infections. Treatment with
recombinant porcine factor VIII has been proven to be effective amongst patients with AHA.
Its effectiveness is enhanced by the possibility of adjusting the dosage to the peak and trough
levels of factor VIII.
We present here a case report of a patient who developed AHA three months after
Sars-Cov-2 infection. He was the one of the first persons in Poland to be treated with rpFVIII.